Source: Nutrition Insight
05 Nov 2018 --- Maritech fucoidan – a bioactive compound extracted from
seaweed – can inhibit the production of key pro-inflammatory biomarkers
that are clinically relevant in acute and chronic gut condition, new
research has found. Maritech fucoidan ingredients are extracted from
wild Undaria pinnatifida and Fucus vesiculosus macroalgae by Australian
biotechnology company Marinova.
When tested in ex-vivo human blood and compared to controls, results
showed that fucoidan inhibited the release of three inflammatory
mediators; TNF-α, IL-1β and IL-6.
TNF-α and IL-1β are drivers of major inflammatory processes. Prolonged
and raised levels are linked to inflammatory bowel disease (IBD), which
affects 10 million people worldwide and includes Crohn’s disease and
ulcerative colitis. Blocking these chemical messengers can result in a
rapid and sustained reduction in disease severity. Maritech fucoidan was
found to reduce TNF-α levels by more than 70 percent and IL-1β by more
than 54 percent.
The pro-inflammatory cytokine IL-6 also plays a central role in
uncontrolled intestinal inflammation. It can alter the balance between
pro-inflammatory and immunosuppressive immune cells, and has been
associated with IBD and colon cancer. In the study, Maritech fucoidan
inhibited the production of IL-6 by more than 43 percent.
“It’s truly exciting that a naturally-derived marine ingredient has
demonstrated such profound anti-inflammatory benefits with great
potential to improve gut and digestive health,” says Dr. Helen Fitton,
Chief Scientist at Marinova, commenting on the significance of the
research.
“Fucoidan has long been valued for its ability to address both local and
systemic inflammation. This activity is ascribed to its biological role
in protecting the seaweed plant from inflammation, caused by UV light
and pathogens.”
The study is part of Marinova’s gut and digestive health research
program. It builds on a series of in vitro and animal models, in which
Maritech fucoidan reportedly inhibited key inflammatory enzymes
expressed in the gastrointestinal tract and reduced the clinical
symptoms and pathology of ulcerative colitis.
“Our fucoidan ingredients already feature in a large number of products
targeting gut health. In fact, gut health is a key growing indication
for Marinova, given the comprehensive research that supports this
application,” Claire Smoorenburg, Marketing & Communications Officer
at Marinova, tells NutritionInsight.
“Following on from these research results, Marinova is embarking on a
clinical trial in the human microbiome. This is part of the company’s
diverse pipeline of R&D planned in gut and digestive health, in
addition to our pillar research areas of immune modulation and
integrative oncology,” she adds.
All Right Reserved:Hunan huacheng Biotech,Inc.Adallen Nutrition,Inc. - Sitemap | Privacy policy | Terms and Conditions | Blog